Bluestar Adisseo Co

Bluestar Adisseo Co has a market price of 11.49 CNY and a market capitalization of 35,386,663,662.93 CNY, with a price-to-earnings ratio of 26.44 and a price-to-book ratio of 1.78. The company's liquidity is characterized as medium, with a current ratio of 2.06 and a debt-to-equity ratio of 0.1, indicating a relatively balanced capital structure. The company's free cash flow is negative at -1,367,847,510 CNY, which may suggest reinvestment in the business or operational challenges. In terms of profitability, Bluestar Adisseo Co has a return on equity of 6.74% and a return on assets of 4.81%, which are metrics that reflect the company's efficiency in generating profits from its equity and assets. The company's gross profit of 4,793,659,330 CNY and operating income of 1,759,572,510 CNY indicate a healthy margin, although the net income of 1,338,144,940 CNY suggests some operational expenses are impacting the bottom line. The company's revenue is concentrated in the pharmaceuticals and medical research sector, with no specific geographic breakdown provided in the available data. This concentration may expose the company to sector-specific risks, such as regulatory changes or shifts in demand for pharmaceutical products. Bluestar Adisseo Co's growth trajectory is reflected in its capital expenditure of -3,702,315,610 CNY, which indicates significant investment in the business. The company's outlook for the current fiscal year is not explicitly provided, but the negative free cash flow and high capital expenditure suggest a focus on expansion or modernization. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity constraint. The company's dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. Recent events, such as analyst estimates, suggest a positive outlook for the company, with a mean price target of 17.35 CNY and a median price target of 17.35 CNY. The mean recommendation of 1.50 indicates a generally positive sentiment among analysts, with two strong-buy and two buy recommendations.